Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study
Mooghali M, Mitchell A, Skydel J, Ross J, Wallach J, Ramachandran R. Characterization of accelerated approval status, trial endpoints and results, and recommendations in guidelines for oncology drug treatments from the National Comprehensive Cancer Network: cross sectional study. BMJ Medicine 2024, 3: e000802. PMID: 38596814, PMCID: PMC11002412, DOI: 10.1136/bmjmed-2023-000802.Peer-Reviewed Original ResearchNational Comprehensive Cancer NetworkNational Comprehensive Cancer Network guidelinesComprehensive Cancer NetworkFood and Drug AdministrationCancer NetworkUS Food and Drug AdministrationCategories of evidenceAccelerated approvalCross sectional studyDrug treatmentConfirmatory trialsClinical benefitTrial resultsOncological indicationsTraditional approvalGuideline recommendationsOutcome measuresSectional studyApproval statusFDA decisionRecommended alignmentOncologyUpdate recommendationsPostapproval trialsGuidelinesPublished research on the human health implications of climate change between 2012 and 2021: cross sectional study
Bartlett V, Doernberg H, Mooghali M, Gupta R, Wallach J, Nyhan K, Chen K, Ross J. Published research on the human health implications of climate change between 2012 and 2021: cross sectional study. BMJ Medicine 2024, 3: e000627. PMID: 38352020, PMCID: PMC10862342, DOI: 10.1136/bmjmed-2023-000627.Peer-Reviewed Original ResearchHealth effects of climate changeHealth research fundingRandom sampleHealth effectsCross sectional studyPeer-reviewed researchWeb of ScienceGrey literatureHealth conditionsSectional studyInclusion criteriaRisk populationHealthHealth impactsHealth implicationsGoogle ScholarResearch articlesNational InstituteFunding sourcesPublication characteristicsResearch fundingPublished researchRiskDisproportionate focusPopulation